MBMaira Souza Oliveira Barreto

Maira Souza Oliveira Barreto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maira Souza Oliveira Barreto has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cardiorenal Syndrome: the bidirectional heart-kidney axis

    by Felipe Gaia de Sousa, Ruthnea Muzzi, Fabiana Queiroz, Suzane Beier, Maira Barreto, Myrian Teixeira

    Cardiorenal syndrome is configured as a set of disorders that affect the heart and/or kidneys, and induce a series of events that alter the entire pre-existing axis between the two systems. Accurate diagnosis and adequate monitoring of patients with cardiovascular and renal diseases have become increasingly frequent. Systems are increasingly interconnected, and paying attention to changes has become fundamental. The objective of this article is to characterize cardiorenal syndrome, highlighting its clinical, pathophysiological, diagnostic, and therapeutic management aspects. Dogs and cats are susceptible to kidney changes that alter blood flow, which can interfere with cardiac function, and the reverse may also occur, particularly if dogs/cats already have the organ affected by other diseases. Furthermore, a series of systemic events can end up interfering even more with the communication between the two systems. The monitoring and follow-up of cardiac and/or nephropathic patients are of fundamental importance in determining the best therapeutic management to be instituted, thereby avoiding complications and injuries to other organs, preventing aggravations to the patient's clinical condition, and reducing their life expectancy.

  • Open Access

    Clinical and Doppler echocardiographic evaluation of rabbits sedated with dexmedetomidine in combination with midazolam and morphine

    by Eduarda Hoffmann Bitencourt, Marcos Paulo Antunes de Lima, Maira Souza Oliveira Barreto, Felipe Gaia de Sousa, Euler Fraga Silva, Eutálio Luiz Mariani Pimenta, Suzane Lilian Beier

    The objective of the present study was to evaluate clinical, cardiorespiratory, and Doppler echocardiographic changes in rabbits sedated with midazolam and morphine combined with or without dexmedetomidine. This study was a blinded, randomized, controlled experiment that included 16 adult male New Zealand rabbits weighing 3.1 ± 0.3 kg. The animals were sedated using one of the following protocols: 1 mg/kg midazolam and 2 mg/kg morphine (MIDA, n = 8), or 25 mg/kg dexmedetomidine, 2 mg/kg morphine and 1 mg/kg midazolam (DEX, n = 8). Sedation latency, duration of the sedation and recovery period, sedation scores, heart rate (HR), respiratory rate (f), peripheral oxygen saturation (SpO2), systolic arterial pressure (SAP), diastolic arterial pressure (DAP), mean arterial pressure (MAP), and recta temperature were recorded, and Doppler echocardiography was performed. Latency periods were 7.3±1.6 min in the DEX group and 10.9 ± 5.0 min in the MIDA group (P = 0.112). Sedation duration was 122.4±14 min in the DEX group and 71.2 ± 32 min in the MIDA group (P = 0.005), whereas recovery time was 35.7±17.7 min in the DEX group and 32.5 ± 25.3 min in the MIDA group (P = 0.743). The sedation scores for the DEX group were significantly higher than those for the MIDA group throughout the monitoring period. Reductions in HR, SAP, MAP, and DAP values were observed in both groups relative to baseline values, and were significantly lower in the DEX group compared to the MIDA group. Minimal Doppler echocardiographic changes were observed. Dexmedetomidine used in combination with midazolam and morphine incremented the quality and duration of sedation in rabbits. Both protocols elicited cardiorespiratory changes that were well-tolerated, with minimal changes in myocardial function.


  • Open Access

    Echocardiographic assessment of felines sedated with dexmedetomidine or xylazine associated with butorphanol

    by Tábata Torres Megda, Felipe Gaia de Sousa, Fernanda Guimarães Miranda, Maira Souza Oliveira Barreto, Cláudio Roberto Scabelo Mattoso, Suzane Lilian Beier

    This prospective cohort study aimed to evaluate by echocardiogram the cardiovascular effects of α2 agents associated with butorphanol in cats. A group of 18 mixed-breed cats with a mean weight of 3.65 + 0.7 kg, with an approximate age of 6 months. The cats were assigned in three groups, XB (Xylazine/butorphanol group) sedation with 0.5 mg/kg of xylazine and 0.5 mg/kg of butorphanol IM; DB (Dexmedetomidine/butorphanol group): sedation with 20 µg/kg of dexmedetomidine and 0.5 mg/kg of butorphanol IM; C: control group which received saline solution in volume approximated to those used in the other groups, IM. Echocardiographic variables as ejection fraction (Simpson's method and M-mode) and left ventricular shortening fraction (M-mode), ejection volume, end-systolic volume and cardiac output (Teichholz), tissue Doppler E' and A' wave velocities and cardiac index were evaluated. There was a reduction in echocardiographic variables compared with the control group, being statistically significant for heart rate, ejection fraction (% by Simpson), shortening fraction (% in M-mode) and end-systolic volume in XB and DB groups, and tissue Doppler E' and A' wave velocity (m/s), E'/A' ratio, cardiac output and cardiac index only in XB group. When compared to each other, XB and DB differed significantly in the tissue Doppler E' and A' wave velocity (m/s), and E'/A' ratio. Xylazine was more deleterious than dexmedetomidine in most of the variables evaluated, leading to a significant reduction in cardiac output and cardiac index at the doses used in this study.


  • Open Access

    Avaliação de células mesenquimais e dapsona para o tratamento de feridas dermonecróticas causadas pelo veneno de Loxosceles laeta em coelhos

    by Guilherme de Caro Martins, Maira Souza Oliveira Barreto, Ana Flávia Machado Botelho, Conrado Gamba, Clara Guerra Duarte, Benito Soto-Blanco, Adriane Pimenta Costa-Val Bicalho, Geovanni Dantas Cassali, Alfredo Miranda de Goes, Carlos Delfin Chávez Olórtegui, et al.

    Resumo Este estudo teve como objetivo avaliar a eficácia das células-tronco mesenquimais (CTMs), isoladas ou associadas à dapsona (DAP), no tratamento de feridas dermonecróticas causadas pelo veneno de Loxosceles laeta. Vinte e cinco coelhos machos foram distribuídos em cinco grupos. O controle negativo recebeu água ultrapura (C-), enquanto todos os outros grupos foram injetados com 20 μg de veneno de L. laeta. Após 4 horas, cada grupo recebeu um dos seguintes tratamentos: PBS (C+), DAP, CTMs e DAP + CTMs. Os animais foram avaliados diariamente durante 12 dias, e feitos registros fotográficos para análise da ferida e no 12º dia, foram eutanasiados e, retiradas amostras de pele para análise histológica. Observou-se que a DAP apresentou o melhor percentual de contração da ferida no terceiro dia. Nos tratamentos com CTMs, observou-se uma contração negativa da ferida tanto para as CTMs isoladas, bem como a associação CTMs + DAP em relação ao PBS, possivelmente, pelo aumento da infamação inicial após a aplicação de células-tronco. Isso é devido ao fato de que as CTMs secretam um amplo espectro de moléculas bioativas como citocinas e fatores de crescimento que favorecem a regeneração. Histologicamente, observou-se que os animais de C+ apresentaram extensas áreas de necrose, úlceras, infiltrado neutrofílico, além de mineralização. Houve aumento de deposição de colágeno no tratamento CTMs + DAP, no entanto, a vascularização permaneceu inalterada. Este é o primeiro relato usando CTMs e CTMs + DAP como tratamento para loxoscelismo cutâneo e mais estudos são necessários para determinar seu uso como terapia alternativa para lesões demonecróticas causadas pela aranha Loxosceles.


  • Open Access

    Evaluation of mesenchymal cells and dapsone for the treatment of dermonecrotic wounds caused by Loxosceles laeta venom in rabbits

    by Guilherme de Caro Martins, Maira Souza Oliveira Barreto, Ana Flávia Machado Botelho, Conrado Gamba, Clara Guerra Duarte, Benito Soto-Blanco, Adriane Pimenta Costa-Val Bicalho, Geovanni Dantas Cassali, Alfredo Miranda de Goes, Carlos Delfin Chávez Olórtegui, et al.

    This study aimed to evaluate the efficacy of mesenchymal stem cells (MSC), alone or associated with dapsone (DAP), in treating dermonecrotic wounds caused by Loxosceles laeta venom. Twenty-five male rabbits were distributed into five groups. Negative control received ultrapure water (C-), whilst all other groups were injected with 20 μg of L. laeta venom. After 4 hours, each group received one of the following treatments: PBS (C+), DAP, MSC, and DAP+MSC. Animals were evaluated daily and photographic records made for analysis of wound area. Twelve days after, animals were euthanized and skin samples removed for histological analysis. We observed that DAP showed the best percentage of wound contraction at day 3. In the treatments using MSCs, a negative value of wound contraction was observed for the isolated MSCs, as well as a lower contraction value for the association of the MSC + DAP when compared to PBS, probably, by the increase in initial infammation after the application of stem cells, due to the fact that MSCs secrete a broad spectrum of bioactive molecules such as cytokines and growth factors that favor regeneration. Histologically, it was observed that animals of C+ showed extensive areas of necrosis, ulcers, neutrophilic infiltrate, and mineralization. Collagen deposition showed increase in MSC+DAP treatment, however vascularization remained unchanged. This is the first report using MSC and MSC+DAP as a treatment for cutaneous loxoscelism and more studies are needed to determine its use as an alternative therapy for dermonecrotic lesions caused by Loxosceles spider.


  • Systolic dysfunction by two-dimensional speckle tracking echocardiography in dogs with parvoviral enteritis

    by C.B. de Abreu, R.A.L. Muzzi, L.E.D. de Oliveira, T. Schulien, M. de R. Coelho, L.A. Alves, C. Hirsch, E.M.S. Dorneles, A.M.B.G. Pinto, M.S.O. Barreto, et al.


  • Open Access

    Extract from Arrabidaea chica (Fridericia chica) leaves show preventive action for the mitigation of doxorubicin-induced cardiotoxicity

    by M.S.O. Barreto, J.L. Carvalho, A.F.R.M. Michel, N.C.R. Corrêa, F.C. Silva, D.A. Gomes, A.M. Goes, M.M. Melo

    A. chica dry leaves (20g) were macerated with 100ml of a mixture ethanol:water (7:3) and took to ultrasonic bath at room temperature for 18h. The A. chica extract (AC) obtained was submitted to partition with solvents (Urbonaviciūte et al., 2006) to obtain a rich flavonoid content extract (2g). Voucher specimens of A. chica were deposited at the herbarium of the Universidade Estadual de Campinas (Campinas, SP, Brazil) under the code UEC 145.956. Mass spectrometry analyses of AC and standards were carried out on a Shimadzu LCMS-IT-TOF system. Among several peaks, the analysis showed one which was identified at 287.079 [M +h]+m/z corresponding to kaempferol. A commercially C. sinensis extract (CS) was used (Sunphenon DCF®, Taiyo Kagaku Co.), containing total polyphenols (>80%), catechins (>80%), epigallocatechins (>45%), and caffeine (<1%) detected by high performance liquid chromatography (HPLC), as informed by the manufacturer.